CTLA-4 inhibition produces durable T cell-driven antitumor responses, but understanding which patients achieve a long-term benefit remains unclear. Deep sequencing of rearranged T cell receptor β (TCRβ) genes can monitor the effects of CTLA-4 inhibition and potentially identify patients with long-term survival
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activat...
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treat...
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion o...
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockade can promote antitumor T cell immunity ...
Cancer cells bear mutations that give rise to novel (neo-) antigens recognised by T cells of the imm...
Tumor antigen-driven selection may expand T cells having T cell receptors (TCRs) of shared antigen s...
In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response t...
In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response t...
Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients...
Contributions: Farah Abdulkhaleq, Niss Larossi and Okanda Ogbonda performed the search, screening an...
Recognition of cancer antigens drives the clonal expansion of cancer-reactive T cells, which is thou...
Transgenic coexpression of a class I-restricted tumor antigen-specific T cell receptor (TCR) and CD8...
CTLA-4 is a key immune checkpoint in maintaining self-tolerance, which can be co-opted by cancer to ...
: Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach to investigate...
Abstract Immune checkpoint blockade (ICB) therapies, which potentiate the body’s natural immune resp...
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activat...
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treat...
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion o...
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) blockade can promote antitumor T cell immunity ...
Cancer cells bear mutations that give rise to novel (neo-) antigens recognised by T cells of the imm...
Tumor antigen-driven selection may expand T cells having T cell receptors (TCRs) of shared antigen s...
In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response t...
In early-stage breast cancer, the degree of tumor-infiltrating lymphocytes (TIL) predicts response t...
Targeting immune inhibitory receptors has brought excitement, innovation and hope to cancer patients...
Contributions: Farah Abdulkhaleq, Niss Larossi and Okanda Ogbonda performed the search, screening an...
Recognition of cancer antigens drives the clonal expansion of cancer-reactive T cells, which is thou...
Transgenic coexpression of a class I-restricted tumor antigen-specific T cell receptor (TCR) and CD8...
CTLA-4 is a key immune checkpoint in maintaining self-tolerance, which can be co-opted by cancer to ...
: Profiling the T-Cell Receptor (TCR) repertoire is establishing as a potent approach to investigate...
Abstract Immune checkpoint blockade (ICB) therapies, which potentiate the body’s natural immune resp...
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activat...
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treat...
Depletion of CD4+ cells using an anti-CD4 monoclonal antibody (anti-CD4 mAb) induces the expansion o...